Edoxaban tosylatye | DU-176b | CAS#1229194-11-9 | 480449-70-5 | factor Xa inhibitor

Edoxaban tosylate monohydrate
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314259

CAS#: 1229194-11-9 (tosylate hydrate)

Description: Edoxaban is a potent, selective factor Xa inhibitor, which has good oral bioavailability. Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is being developed by Daiichi Sankyo. It was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and nonÂ–central-nervous-system systemic embolism.

Chemical Structure

Edoxaban tosylate monohydrate

CAS# 1229194-11-9 (tosylate hydrate)

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 314259
Name: Edoxaban tosylate monohydrate
CAS#: 1229194-11-9 (tosylate hydrate)
Chemical Formula: C31H40ClN7O8S2
Exact Mass: 0.00
Molecular Weight: 738.272
Elemental Analysis: C, 50.43; H, 5.46; Cl, 4.80; N, 13.28; O, 17.34; S, 8.69

Price and Availability

Size	Price	Availability
50mg	USD 150	Ready to ship
100mg	USD 225	Ready to ship
200mg	USD 385	Ready to ship
500mg	USD 750	Ready to ship
1g	USD 1250	Ready to ship
2g	USD 2050	Ready to ship
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: DU-176; DU 176; DU176; DU176b; DU-176b; DU 176b; Edoxaban; Edoxaban tosylate monohydrate, trade name Lixiana; Savaysa;

IUPAC/Chemical Name: N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide 4-methylbenzenesulfonate hydrate

InChi Key: PSMMNJNZVZZNOI-SJILXJHISA-N

InChi Code: InChI=1S/C24H30ClN7O4S.C7H8O3S.H2O/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10;/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10);1H2/t13-,15-,17+;;/m0../s1

SMILES Code: O=C(NC1=NC=C(Cl)C=C1)C(N[C@@H]2[C@H](NC(C(S3)=NC4=C3CN(C)CC4)=O)C[C@@H](C(N(C)C)=O)CC2)=O.CC5=CC=C(S(=O)(O)=O)C=C5.[H]O[H]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# 1229194-11-9 (Edoxaban tosylate hydrate); 480449-70-5 (Edoxaban free base).

Product Data:

Product Data

Certificate of Analysis:

View CoA: current batch, Lot#C8R08B08

QC Data:

View QC data: current batch, Lot#C8R08B08

Safety Data Sheet (SDS):

View Safety Data Sheet (SDS)

Instruction:

View handling instruction

Biological target:	Edoxaban tosylate monohydrate (DU-176b monohydrate) is a factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively.
In vitro activity:	Edoxaban exhibited a dose-dependent increase in anti-FXa activity; additional dilutions with normal plasma were required for edoxaban concentrations greater than 0.2 μg/mL (Fig. 4a). An assay specific for direct FXa inhibitors that is unaffected by the presence of heparin (Hyphen BioMed method) showed a concentration-dependent inhibition of OD405 by edoxaban, confirming a direct inhibitory effect on FXa activity (Fig. 4b). Reference: Thromb Res. 2012 Apr;129(4):e77-82. https://pubmed.ncbi.nlm.nih.gov/21851967/
In vivo activity:	In this LPS-induced thrombosis rat model, the direct FXa inhibitor, edoxaban, significantly inhibited the hypercoagulation, the fibrin deposition in the liver, and the elevation of the liver damage parameters in a dose-dependent manner. Furthermore, edoxaban significantly reduced mortality caused by LPS. However, edoxaban did not suppressed the elevation of inflammatory cytokines and the kidney damage. Reference: J Thromb Thrombolysis. 2021 Feb 3 : 1–9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856452/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	75.0	101.59
	Water	1.0	1.35

Preparing Stock Solutions

The following data is based on the product molecular weight 738.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Hillarp A, Strandberg K, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Lindahl TL. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays. Scand J Clin Lab Invest. 2018 Nov-Dec;78(7-8):575-583. doi: 10.1080/00365513.2018.1522664. Epub 2018 Oct 2. PMID: 30278787. 2. Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res. 2012 Apr;129(4):e77-82. doi: 10.1016/j.thromres.2011.07.026. Epub 2011 Aug 17. PMID: 21851967. 3. Nagata N, Kawasumi M, Fujimura A, Ando H. Edoxaban Dosing Time Affects Blood Coagulation Inhibition in Rats. TH Open. 2021 Apr 14;5(2):e107-e112. doi: 10.1055/s-0041-1725041. PMID: 33870074; PMCID: PMC8046513. 4. Morishima Y, Shibutani T, Noguchi K, Ito Y, Honda Y. Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats. J Thromb Thrombolysis. 2021 Feb 3:1–9. doi: 10.1007/s11239-021-02381-y. Epub ahead of print. PMID: 33534029; PMCID: PMC7856452.
In vitro protocol:	1. Hillarp A, Strandberg K, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Lindahl TL. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays. Scand J Clin Lab Invest. 2018 Nov-Dec;78(7-8):575-583. doi: 10.1080/00365513.2018.1522664. Epub 2018 Oct 2. PMID: 30278787. 2. Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res. 2012 Apr;129(4):e77-82. doi: 10.1016/j.thromres.2011.07.026. Epub 2011 Aug 17. PMID: 21851967.
In vivo protocol:	1. Nagata N, Kawasumi M, Fujimura A, Ando H. Edoxaban Dosing Time Affects Blood Coagulation Inhibition in Rats. TH Open. 2021 Apr 14;5(2):e107-e112. doi: 10.1055/s-0041-1725041. PMID: 33870074; PMCID: PMC8046513. 2. Morishima Y, Shibutani T, Noguchi K, Ito Y, Honda Y. Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats. J Thromb Thrombolysis. 2021 Feb 3:1–9. doi: 10.1007/s11239-021-02381-y. Epub ahead of print. PMID: 33534029; PMCID: PMC7856452.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548805/ PubMed PMID: 31644112.

2: Cervantes CE, Merino JL, Barrios V. Edoxaban for the prevention of stroke in patients with atrial fibrillation. Expert Rev Cardiovasc Ther. 2019 Apr;17(4):319-330. doi: 10.1080/14779072.2019.1598263. Epub 2019 Mar 27. Review. PubMed PMID: 30897988.

3: Pharmacoeconomic Review Report: Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK535088/ PubMed PMID: 30540394.

4: CADTH Canadian Drug Expert Committee Final Recommendation: Edoxaban: (Lixiana — Servier Canada Inc.): Indication: Venous Thromboembolic Events [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK534995/ PubMed PMID: 30540393.

5: Clinical Review Report: Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK535077/ PubMed PMID: 30540391.

6: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500740/ PubMed PMID: 29999799.

7: Linkins LA MD, MSc, FRCPC. Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism. BMJ Evid Based Med. 2018 Dec;23(6):230. doi: 10.1136/bmjebm-2018-111007. Epub 2018 Jun 29. Review. PubMed PMID: 29959155.

8: Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr. Available from http://www.ncbi.nlm.nih.gov/books/NBK475920/ PubMed PMID: 29341555.

9: Institute for Quality and Efficiency in Health Care. Edoxaban -- Benefit Assessment According to §35a Social Code Book V [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2015 Oct 28. Available from http://www.ncbi.nlm.nih.gov/books/NBK458399/ PubMed PMID: 29144699.

10: Hammwöhner M, Goette A. The safety of edoxaban for treating atrial fibrillation. Expert Opin Drug Saf. 2017 Nov;16(11):1295-1303. doi: 10.1080/14740338.2017.1372418. Epub 2017 Sep 18. Review. PubMed PMID: 28862063.

11: O'connor CT, Kiernan TJ, Yan BP. The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):725-739. doi: 10.1080/17425255.2017.1338274. Epub 2017 Jun 13. Review. PubMed PMID: 28571507.

12: Gibson CM, Finks SW. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape? Am J Med. 2017 Aug;130(8):900-906. doi: 10.1016/j.amjmed.2017.02.048. Epub 2017 Apr 6. Review. PubMed PMID: 28390791.

13: Scheen AJ, Lancellotti P. [Edoxaban (LIXIANA®) : new oral anticoagulant forthetreatment and secondary prevention of thromboembolic disease]. Rev Med Liege. 2016 Nov;71(11):517-524. Review. French. PubMed PMID: 28387109.

14: Weiss TW, Rohla M, Dieplinger B, Domanovits H, Fries D, Vosko MR, Gary T, Ay C. [Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper]. Wien Med Wochenschr. 2018 Apr;168(5-6):133-143. doi: 10.1007/s10354-017-0548-4. Epub 2017 Feb 24. Review. German. PubMed PMID: 28236004.

15: Curto A, Curto D, Sanchez J. Managing patients taking edoxaban in dentistry. J Clin Exp Dent. 2017 Feb 1;9(2):e308-e311. doi: 10.4317/jced.53431. eCollection 2017 Feb. Review. PubMed PMID: 28210454; PubMed Central PMCID: PMC5303336.

16: De Caterina R, Ageno W, Boriani G, Colonna P, Ghirarduzzi A, Patti G, Rossini R, Rubboli A, Schinco P, Agnelli G. Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. Adv Ther. 2017 Mar;34(3):620-637. doi: 10.1007/s12325-017-0488-9. Epub 2017 Feb 13. Review. PubMed PMID: 28194578; PubMed Central PMCID: PMC5350200.

17: Poulakos M, Walker JN, Baig U, David T. Edoxaban: A direct oral anticoagulant. Am J Health Syst Pharm. 2017 Feb 1;74(3):117-129. doi: 10.2146/ajhp150821. Review. PubMed PMID: 28122753.

18: Aspromonte N, Colivicchi F. Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure. Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):113-122. Epub 2016 Nov 18. Review. PubMed PMID: 27819149.

19: Minguet J, Sims HM, Smith KH, Bramlage P. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Expert Rev Clin Pharmacol. 2017 Jan;10(1):5-15. doi: 10.1080/17512433.2016.1258301. Epub 2016 Nov 17. Review. Erratum in: Expert Rev Clin Pharmacol. 2017 Jan;10 (1):1. PubMed PMID: 27817212.

20: AlHajri L, Jabbari S, AlEmad H, AlMahri K, AlMahri M, AlKitbi N. The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review. J Cardiovasc Pharmacol Ther. 2017 May;22(3):230-238. doi: 10.1177/1074248416675732. Epub 2016 Nov 2. Review. PubMed PMID: 27811198.

Your view history

Edoxaban tosylate monohydrate featured